Background: Triple-negative breast cancer (TNBC) may be more sensitive to platinum. The aim of this study was to compare the different pathologic complete response (pCR) in patients with locally advanced TNBC treated with platinum-based neoadjuvant chemotherapy with nonplatinum regimen. Methods: Eligible locally advanced TNBC women received either paclitaxel (or docetaxel)- carboplatin (TC) or paclitaxel (or docetaxel)- epirubicin (TE) q3w for up to 4-6 cycles. The primary end point was the rate of pathological complete response (pCR), defined as the absence of invasive cancer in the breast and axilla at the time of surgery. The second end point was the clinical response rate and recurrence free survival (RFS). Results: In total, 92 patients were enrolled between January 2009 and December 2012. Of these, 43 patients were assigned to TC group, and 49 to TE group. The pCR rate was higher in TC group than in TE group (37.2% versus 16.1%, p=0.032). The clinical response rates were similar in TC and TE group (83.7% versus 87.8%, p=0.500). The incidence of grade 3–4 neutropenia (TC: 39.5% versus TE: 46.9%, p=0.399) and febrile neutropenia, were not significantly different between two groups. Peripheral neuropathy was frequent but never severe. G3 alopecia was more frequent in TE group than in TC group. RFS has not been evaluated yet because of limited follow-up time. Conclusions: This study suggested that platinum-based chemotherapy was superior to nonplatinum regimen in the neoadjuvant treatment of locally advanced TNBC, as measured by pCR. Further large-scale prospective randomized trials are warranted.